[Press release] Bioplus decides to invest 2.3 billion won in ProCell Therapeutics, Inc 2022년 July 14일 By bioplubiz
[Press release] BioPlus’s 2 types of hyaluronic acid fillers obtained special import license from China 2022년 July 11일 By bioplubiz
[Press release] This year’s goal is to double the operating profit…Targeting the largest market for filler in the U.S. and China 2022년 June 19일 By bioplubiz
[Press release] BioPlus signs overall medical device contract with Chimin health management, a medical pharmaceutical specialist in China 2022년 May 9일 By bioplubiz
[Press release] BioPlus Co-develops Next Generation Botulinum Toxin with ProCell Therapeutics 2022년 March 28일 By bioplubiz
[Press release] BioPlus’s operating profit in 2021 is 18.3 billion won. “The best performance since its foundation” 2022년 February 16일 By bioplubiz
[Press release] Co-development MOU with BioPlus, Noblegen, and Gachon University for virus treatments was signed 2021년 December 23일 By bioplubiz
[Press release] Will BioPlus continue its surprise performance next year? It’s about to enter China, the biggest market 2021년 December 16일 By bioplubiz
